Zoetis Stock: Is ZTS Underperforming the Healthcare Sector?

Company Overview - Zoetis Inc. is valued at a market capitalization of $54.4 billion and is a leader in the animal health sector, involved in the discovery, development, manufacture, and commercialization of various health solutions for animals [1] - The company is categorized as a "large-cap stock" due to its market cap exceeding $10 billion, indicating its scale and market presence [2] Stock Performance - ZTS stock has faced challenges recently, having reached a 52-week high of $177 on March 10, 2025, but is currently down 26.7% from that peak [3] - Over the past three months, ZTS stock increased by 1.6%, slightly outperforming the State Street Healthcare Select Sector SPDR ETF (XLV), which experienced a marginal decline [3] - In the last 52 weeks, ZTS shares have declined by 21.4%, underperforming XLV, which delivered a 6.5% return during the same period [6] Financial Performance - On February 13, Zoetis reported better-than-expected Q4 2025 earnings, with revenue growing 3% year-over-year to $2.4 billion, surpassing market expectations [7] - The adjusted EPS for the quarter was $1.48, also exceeding Wall Street estimates [7] - For the full year, Zoetis anticipates earnings in the range of $7 to $7.10 per share, with revenue projected between $9.82 billion and $10.03 billion [7] Competitive Position - Compared to its peer, United Therapeutics Corporation (UTHR), Zoetis has underperformed, with UTHR shares surging 57.9% over the past 52 weeks and rising 3.1% in the last three months [8] - Wall Street analysts maintain a cautious optimism regarding ZTS, with a consensus rating of "Moderate Buy" among 17 analysts and a mean price target of $151.13, indicating a 16.5% upside potential from current levels [8]